EP Patent

EP2409967A1 — Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Assigned to Novartis Pharma GmbH Austria · Expires 2012-01-25 · 14y expired

What this patent protects

Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]-phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.

USPTO Abstract

Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]-phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.

Drugs covered by this patent

panobinostat-lactate (PANOBINOSTAT LACTATE)

Patent Metadata

Patent number: EP2409967A1
Jurisdiction: EP
Classification: —
Expires: 2012-01-25
Drug substance claim: No
Drug product claim: No
Assignee: Novartis Pharma GmbH Austria
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.